{"id":250826,"date":"2022-07-25T00:00:00","date_gmt":"2022-07-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/cutron0022-2022-biopharma-acute-lymphoblastic-leukemia-current-treatment\/"},"modified":"2026-04-26T11:18:31","modified_gmt":"2026-04-26T11:18:31","slug":"cutron0022-2022-biopharma-acute-lymphoblastic-leukemia-current-treatment-acute-lymphoblastic-leukemia-current-treatment","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0022-2022-biopharma-acute-lymphoblastic-leukemia-current-treatment-acute-lymphoblastic-leukemia-current-treatment\/","title":{"rendered":"Acute Lymphoblastic Leukemia &#8211; Current Treatment &#8211; Acute Lymphoblastic Leukemia | Current Treatment: Physician Insights | US"},"content":{"rendered":"<div>\n<p>Acute lymphoblastic leukemia (<abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr>) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line treatment of B-cell <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr>; however, the treatment paradigm has been transformed over the past two decades with the advent of targeted agents such as tyrosine kinase inhibitors (Novartis\u2019s Gleevec, Bristol Myers Squibb\u2019s Sprycel, and Takeda\u2019s Iclusig). Bispecific T-cell engagers (Amgen\u2019s Blincyto), antibody-drug conjugates (Pfizer\u2019s Besponsa), and <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies (Novartis\u2019s Kymriah, Gilead\u2019s Tecartus) have further diversified treatment options for relapsed or refractory (<abbr title=\"relapsed\/refractory\">R\/R<\/abbr>) disease. The emergence of these targeted therapies has improved the prognosis for patients and continues to expand the <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> treatment armamentarium.<\/p>\n<\/div>\n<div>\n<p><strong>Questions answered<\/strong><\/p>\n<\/div>\n<ul class=\"BulletListStyle1 BCX0 SCXP59830635 round-bullets\">\n<li>What are the patient shares of key therapies and regimens used for pediatric, young adult, and adult <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> patients?<\/li>\n<li>What is the uptake of <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies (Kymriah and Tecartus) in younger and older <abbr title=\"relapsed\/refractory\">R\/R<\/abbr>\u00a0<abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> patient populations?<\/li>\n<li>How do drug-treatment rates vary across key <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> patient populations and by line of therapy?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing patterns in <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr>?<\/li>\n<\/ul>\n<div>\n<p><b>Product description<\/b><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><b>Markets covered: <\/b>United States.<\/p>\n<p><b>Primary research: <\/b>Survey of 100 U.S. hematologist-oncologists.<\/p>\n<p><b>Key drugs covered: <\/b>Kymriah, Tecartus, Blincyto, Besponsa, Gleevec, Sprycel, Iclusig, and Marqibo.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-250826","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-lymphoblastic-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250826\/revisions"}],"predecessor-version":[{"id":283109,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250826\/revisions\/283109"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}